Anti-Diabetes Drugs - Israel | Statista Market Forecast

The Anti-Diabetes Drugs market in Israel is expected to witness a significant increase in revenue, reaching US$202.50m by the year 2024.
This projection indicates a promising future for the market.
Furthermore, it is anticipated that the market will continue to grow steadily, with an annual growth rate (CAGR 2024-2029) of 7.26%, resulting in a market volume of US$287.40m by the year 2029.
When compared globally, it is worth noting that United States will generate the highest revenue in the Anti-Diabetes Drugs market, with an estimated value of US$37.84bn in the year 2024.
This highlights the dominance of the United States in this market.
Israel is at the forefront of research and development for innovative anti-diabetes drugs, driving advancements in treatment options.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Israel has been experiencing steady growth in recent years.

Customer preferences: As in many countries, there has been an increase in the prevalence of diabetes in Israel, which has led to a growing demand for anti-diabetes drugs. Patients in Israel are generally looking for effective drugs that can help them manage their condition and improve their quality of life. Additionally, there is a growing interest in natural remedies and alternative therapies, as many patients are looking for ways to manage their diabetes without relying solely on medication.

Trends in the market: One trend that has been observed in the Israeli market is a shift towards newer, more innovative drugs. This is partly driven by the fact that many of the older drugs have gone off-patent, making them more affordable and accessible to patients. As a result, pharmaceutical companies are investing more in research and development to come up with new drugs that can offer better outcomes for patients.Another trend in the market is the growing use of combination therapies. Many patients in Israel are now being prescribed multiple drugs to manage their diabetes, as this can often lead to better outcomes than using a single drug alone. This trend is expected to continue as more combination therapies become available on the market.

Local special circumstances: One factor that has contributed to the growth of the Anti-Diabetes Drugs market in Israel is the country's strong healthcare system. Israel has a universal healthcare system that provides coverage to all citizens, which means that patients have access to a wide range of drugs and treatments. Additionally, the country has a well-developed pharmaceutical industry, which has helped to drive innovation and competition in the market.

Underlying macroeconomic factors: Israel has a strong and growing economy, which has helped to drive growth in the Anti-Diabetes Drugs market. The country has a highly educated population and a well-developed healthcare system, which means that patients are able to access the drugs and treatments they need to manage their condition. Additionally, the government has implemented policies to encourage innovation in the pharmaceutical industry, which has helped to drive the development of new drugs and therapies. Overall, the Anti-Diabetes Drugs market in Israel is expected to continue growing in the coming years, driven by a combination of demographic and economic factors.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.